Neurosense Therapeutics
Quarterly Financials
| Values in thousands | 2024-12-31 |
|---|---|
Revenue | $0 |
EBITDA | |
EBIT | -1,771 |
Net Income | -1,801 |
Net Change In Cash | 0 |
Free Cash Flow | |
Cash | 3,378 |
Basic Shares | 23,228 |
Annual Financials
| Values in thousands | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $0 |
Gross Profit | -22 | -97 | -89 | |
EBITDA | -11,069 | -9,877 | -9,638 | -12,229 |
EBIT | -11,085 | -9,899 | -9,659 | -12,318 |
Net Income | -11,125 | -10,210 | -10,107 | -12,340 |
Net Change In Cash | 0 | 0 | 0 | 0 |
Free Cash Flow | -7,679 | -10,138 | -8,383 | -7,656 |
Cash | 166 | 3,378 | 2,640 | 3,543 |
Basic Shares | 25,481 | 18,602 | 13,640 | 11,505 |
Earnings Calls
| Quarter | EPS |
|---|---|
2026-03-31 | $0 |
2025-12-31 | $0 |
2025-09-30 | -$0.04 |
2025-06-30 | -$0.19 |